Cleveland BioLabs Doses First Volunteers In Second Safety Study For CBLB502
Cleveland BioLabs, Inc. announced that the first healthy volunteers have been dosed in the second human safety study for CBLB502, a drug under development for the treatment of Acute Radiation Syndrome (ARS). CBLB502 is being developed by Cleveland BioLabs under the FDA’s Animal Efficacy Rule to treat Acute Radiation Syndrome (ARS) or radiation poisoning from any exposure to radiation such as a nuclear or radiological weapon / dirty bomb, or from a nuclear accident.
For the full story, Click Here






A research conducted at University of California Irvine Medical Center has developed a new therapy that, if delivered endoscopically, in combination with radiation therapy and chemotherapy, can prove beneficial for patients suffering from advanced esophageal cancer. The new biological therapy (TNFerade), in which an agent preventing tumor is injected, was tried on 24 patients of the highly fatal form of cancer. The treatment has a non-replicating virus, engineered to deliver the gene for a protein that fights cancer.
A recent study conducted at
Pancreatic cancer, difficult to detect in the early stages and having incidence of recurring in the postoperative stage, has found an effective treatment in chemo-radiotherapy. Gemcitabine, an effective radio-sensitizer, has led to better results in patients suffering with this form of cancer, increasing survival with a clinical benefit. A study conducted by Pancreatic Diseases Branch of Kyushu University in Japan, using a schedule that infused gemcitabine twice weekly for patients suffering with locally advanced pancreatic cancer gave positive results on the survival rate and median survival time.